Human KRT13 knockout A-431 cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
- WB
Unknown
Western blot - Human KRT13 knockout A-431 cell lysate (AB269647)
False colour image of Western blot : Anti-Cytokeratin 13 antibody [EPR3672] staining at 1/2000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab133340 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate ab269647). To generate this image, wild-type and Krt13 knockout A431 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
false
- WB
Unknown
Western blot - Human KRT13 knockout A-431 cell lysate (AB269647)
False colour image of Western blot : Anti-Cytokeratin 13 antibody [AE8] staining at 1 μg/ml, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab16112 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate ab269647). To generate this image, wild-type and Krt13 knockout A431 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.
false
- WB
Unknown
Western blot - Human KRT13 knockout A-431 cell lysate (AB269647)
False colour image of Western blot : Anti-Cytokeratin 13 antibody [EPR3671] staining at 1/100000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab92551 was shown to bind specifically to Cytokeratin 13. A band was observed at 51 kDa in wild-type A431 cell lysates with no signal observed at this size in Krt13 knockout cell line ab269483 (knockout cell lysate ab269647). To generate this image, wild-type and Krt13 knockout A431 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution.
false
- NGS
Supplier Data
Next Generation Sequencing - Human KRT13 knockout A-431 cell lysate (AB269647)
Knockout achieved by CRISPR/Cas9; X = 5 bp deletion; Frameshift : 100%
Reactivity data
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
This protein participates in maintaining the structural framework and dynamics within epithelial tissues. As part of the cytoskeletal complex cytokeratin 13 supports cellular resilience against mechanical stress. It interacts with other cytokeratins contributing to the formation of a robust keratin filament network essential for epithelial cell function and differentiation. Its expression and regulation are key to the homeostasis of the tissues where it is found ensuring proper cell division and tissue integrity.
Pathways
Cytokeratin 13 integrates into epithelial cell differentiation and repair processes. It is involved in the epithelial-mesenchymal transition (EMT) pathway important for tissue development wound healing and cancer metastasis. During the EMT process cytokeratin 13 often works alongside proteins like E-cadherin and Vimentin mediating changes in epithelial cell architecture and polarity. This modulation is essential for cellular plasticity and response to environmental cues.
Quality control
STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Female
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com